What Happened
- Indian patents protecting semaglutide (brand names Ozempic for diabetes, Wegovy for obesity) expired on March 20, 2026, triggering a wave of generic GLP-1 drugs from domestic pharmaceutical companies.
- Over 50 low-cost generic versions are entering the market, with prices as low as ₹750 per weekly injection (Sun Pharma's version) compared to the original brand price of ₹8,800–₹10,000 per month — a reduction of 60–90%.
- The anti-obesity drug market in India was valued at $165 million and is expected to reach $880 million by 2030.
- GLP-1 drugs have moved beyond clinical use into lifestyle applications — reportedly being added to bridal packages and used for aesthetic weight loss, raising concerns about medically unsupervised use.
- A government advisory mandated that GLP-1 drugs can only be prescribed by endocrinologists, internal medicine specialists, and cardiologists and cannot be purchased over the counter.
- Quality control remains a concern: standardised testing methods for GLP-1 peptide compounds are not yet widely enforced across Indian labs.
Static Topic Bridges
GLP-1 Receptor Agonists — Pharmacology and Mechanism
GLP-1 (Glucagon-Like Peptide-1) is an incretin hormone secreted by intestinal L-cells in response to food intake. It stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on the brain's hypothalamus to reduce appetite — an effect colloquially termed "food noise reduction." GLP-1 receptor agonists (GLP-1 RAs) mimic this hormone's action and were originally developed as anti-diabetic drugs before their weight-loss effects were discovered.
- Semaglutide (active ingredient in Ozempic/Wegovy) is a weekly-injected GLP-1 RA developed by Novo Nordisk (Denmark)
- Clinical trials showed ~15% body weight reduction in non-diabetic obese individuals (STEP trials, 2021)
- Mechanism: binds GLP-1 receptors in pancreatic beta cells (insulin stimulation), alpha cells (glucagon suppression), and the central nervous system (appetite suppression)
- Other GLP-1 RAs: tirzepatide (Mounjaro — dual GIP/GLP-1 agonist by Eli Lilly), liraglutide (Victoza/Saxenda)
- Side effects: nausea, vomiting, pancreatitis risk, and concerns about muscle mass loss (sarcopenia) — particularly relevant for the Indian phenotype
Connection to this news: India's patent expiry has democratised access to semaglutide, but the same pharmacology that makes it effective also makes unsupervised use risky — especially given India's distinct metabolic profile.
The 'Thin-Fat Indian' Phenotype and Metabolic Obesity
South Asian populations, including Indians, exhibit a distinct metabolic profile termed the "Thin-Fat Indian" or TOFI (Thin Outside, Fat Inside) phenotype. Indian newborns and adults show higher body fat (especially visceral and ectopic fat — fat deposited around organs) at lower body weights compared to other ethnicities. This makes standard BMI-based obesity thresholds insufficient for India.
- The WHO has recommended lower BMI cut-offs for Asians: overweight ≥23 kg/m², obese ≥27.5 kg/m² (versus the global standard of ≥25 and ≥30)
- Indians develop type 2 diabetes at much lower BMI levels (often 23–25 vs. 30+ in Europeans) — attributed to higher abdominal fat deposition and lower muscle mass
- India had approximately 89.8 million adults living with diabetes in 2024 (10.5% adult prevalence), the highest absolute number globally
- National Family Health Survey (NFHS-5, 2019–21): 24% of Indian women and 23% of Indian men are overweight or obese — over 180 million people
- ICMR-INDIAB study: ~43.3% of adults show metabolic obesity without generalised obesity — high metabolic risk despite normal BMI
Connection to this news: GLP-1 drugs address both obesity and glycaemic control — directly relevant to India's dual burden of the Thin-Fat phenotype (where metabolic risk exceeds apparent weight) and the world's largest diabetic population.
India's Pharmaceutical Industry — Generic Drug Manufacturing and Patent Law
India is the world's pharmacy of the world, supplying ~20% of global generic medicine exports by volume. India's patent law framework under the Patents Act, 1970 (amended 2005) was designed to balance innovation incentives with public health access — a position that has been tested in landmark Supreme Court cases.
- TRIPS Agreement (1994): WTO members must protect patents for 20 years; India implemented pharmaceutical product patents only from January 1, 2005 (transition period under TRIPS)
- Section 3(d) of the Patents Act, 1970: Bars patents on new forms of known substances (salts, polymorphs) unless they demonstrate enhanced efficacy — a uniquely Indian provision upheld in Novartis AG v. Union of India (2013) by the Supreme Court
- Compulsory Licensing (Section 84): Allows manufacture of patented drugs without consent if: (i) reasonable requirements of the public not satisfied, (ii) not available at reasonably affordable price, or (iii) not worked in India. Used notably in Natco Pharma v. Bayer (2012, for Nexavar)
- Indian pharma companies (Sun Pharma, Cipla, Torrent, Biocon) are global leaders in peptide generics manufacturing — semaglutide is a complex peptide requiring advanced synthesis
Connection to this news: The semaglutide patent expiry (March 2026) — not requiring compulsory licensing — represents the standard patent lifecycle at work, allowing Indian generics manufacturers to legally produce affordable versions, potentially transforming access to a drug that costs $1,000+/month in the US.
Public Health Regulation of Drugs — India's Framework
Drug regulation in India is governed by the Drugs and Cosmetics Act, 1940 and overseen by the Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare. New drugs require approval from the Drug Controller General of India (DCGI), and prescriptions for scheduled drugs are mandatory.
- Semaglutide is classified as a Schedule H drug in India — available only on prescription from qualified medical practitioners
- CDSCO approval for generic semaglutide requires bioequivalence studies demonstrating that the generic performs the same as the originator in the human body
- Concerns about the GLP-1 "lifestyle" market (use by non-diabetic, non-obese individuals for aesthetic weight loss) fall outside approved indications — termed off-label use, which is legal but unregulated
- India lacks a comprehensive anti-obesity national programme analogous to its National Diabetes Programme — obesity is often addressed within NCD (Non-Communicable Disease) frameworks
- Eat Right India (FSSAI initiative) and Fit India Movement are existing government programmes but do not address pharmacological obesity treatment at scale
Connection to this news: The government advisory restricting GLP-1 prescriptions to specialists is a step within the DCA framework, but quality control gaps and the scale of India's obesity burden suggest a need for updated NCD policy that formally incorporates pharmacological treatment pathways.
Key Facts & Data
- Indian semaglutide patents expired: March 20, 2026
- Generic semaglutide price (India): as low as ₹750/weekly injection (Sun Pharma); vs. ₹8,800–₹10,000/month (originator brand)
- Generic price reduction: 60–90% below originator price
- Number of generic versions entering market: 50+
- India's anti-obesity drug market: $165 million (2026 est.); projected $880 million by 2030
- Adults living with diabetes in India (2024): ~89.8 million (10.5% prevalence)
- Overweight or obese Indians: 24% women, 23% men (NFHS-5) — over 180 million people
- WHO Asia-specific BMI thresholds: overweight ≥23, obese ≥27.5 kg/m²
- GLP-1 prescribers in India (per government advisory): endocrinologists, internal medicine specialists, cardiologists only
- Section 3(d) of Patents Act, 1970: bars trivial modification patents; upheld in Novartis v. India (2013)
- India's generic drug export share: ~20% of global generic volume